Curis (NASDAQ:CRIS) Announces Quarterly Earnings Results

Curis (NASDAQ:CRIS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.13, Zacks reports. The company had revenue of $3.18 million during the quarter, compared to analysts’ expectations of $2.86 million.

Curis Stock Performance

CRIS stock traded down $0.15 during trading on Friday, hitting $1.31. 233,192 shares of the company’s stock traded hands, compared to its average volume of 94,923. Curis has a 52 week low of $1.02 and a 52 week high of $4.70. The stock has a market capitalization of $16.37 million, a price-to-earnings ratio of -0.27 and a beta of 3.88. The business has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.85.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Curis stock. Maverick Capital Ltd. increased its stake in Curis, Inc. (NASDAQ:CRIS) by 7.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 681,381 shares of the biotechnology company’s stock after acquiring an additional 49,554 shares during the period. Maverick Capital Ltd. owned approximately 5.45% of Curis worth $1,472,000 as of its most recent SEC filing. 29.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Curis currently has a consensus rating of “Hold” and a consensus target price of $17.00.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.